Aptus Pharma has scheduled a board meeting on June 12, 2026, to consider proposals for raising capital through preferential allotment and borrowings. The meeting, set to take place at the corporate office in Rajkot, Gujarat, will evaluate the issuance of equity shares or other eligible securities via preferential allotment. Additionally, the board will deliberate on securing borrowings from banks, financial institutions, or other lenders to meet the company's funding requirements.

The board intends to authorize the Managing Director to identify and interact with prospective investors and allottees for the preferential allotment. The Managing Director will also be tasked with approaching prospective lenders to secure the best available terms for borrowings. The company noted that the current intimation pertains only to the consideration of the proposal in principle at an exploratory stage.

Specific details regarding the fund-raising exercise, including the quantum of funds, the number of securities to be issued, the identity of allottees, and the issue price, are yet to be finalized. The company stated that these material details will be disclosed to the stock exchanges in accordance with the SEBI LODR Regulations and SEBI ICDR Regulations at the appropriate stage.

In conjunction with the board meeting, Aptus Pharma has announced the closure of its trading window for all designated persons and their immediate relatives. The window closed effective June 9, 2026, at 5:00 p.m., coinciding with the intimation of the meeting. The restriction will remain in effect until 48 hours after the outcome of the board meeting is disseminated to the stock exchanges, in compliance with SEBI PIT Regulations.

The proposed fund-raising activities are subject to necessary approvals from shareholders and relevant regulatory and statutory authorities. The board's decision will determine the subsequent steps for both the preferential allotment and the borrowing plans.

Aptus Pharma Limited has undertaken a strategic brand-building initiative by taking over the Baby Care Room at Rajkot Hirasar Airport. This move is aimed at promoting the company's upcoming baby care and OTC product portfolio. The initiative was disclosed to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company stated that this premium placement at one of Gujarat's growing airports is designed to enhance brand visibility among travelers and families. By securing this location, Aptus Pharma aims to strengthen awareness of its expanding healthcare product range. The focus is on establishing a stronger presence in the OTC and baby care segment.

Strategic Objectives

The initiative is expected to contribute positively towards the company's brand positioning and market presence. Management believes that the visibility at the airport will aid in improving market reach and strengthening customer trust. The company described the initiative as part of the ordinary course of business.

Operational Divisions

Aptus Pharma operates through several divisions to manage its diverse product portfolio. These divisions include:

The brand promotion at Rajkot Hirasar Airport aligns with the company's broader strategy to expand its footprint in the healthcare and personal care markets.